Krumholz was referring to a report, issued by the Senate Finance Committee, concluding that even as Glaxo scientists were voicing warnings about the safety of the blockbuster diabetes drug Avandia, the company was taking aggressive measures to discredit critics who publicly raised similar concerns.
"The pages of the Senate report read like a spy novel: Glaxo receiving confidential documents leaked by a sympathetic academic who consulted for the company; the company embarking on a campaign to intimidate critics who warned about potential safety issues with the drug; and executives pulling strings to release data early from a scientific study that was supposedly controlled by an 'independent' committee of researchers," Krumholz said'
Read more...
No comments:
Post a Comment
Thanks for your comment it is much appreciated.